Orally Active Forms of DMT, 5-MeO-DMT, and Long-Acting MDMA for the Treatment of Neuropsychiatric Disorders.
ACS medicinal chemistry letters April 13, 2023 DOI: 10.1021/acsmedchemlett.3c00077 via PubMed
Summary
AI-generated from the abstractThis patent describes prodrugs—compounds that are metabolically converted into active forms—of DMT, 5-MeO-DMT, and MDMA. When given to a subject, these prodrugs could potentially be used to treat neurological diseases. The disclosure outlines methods for potentially treating conditions including major depressive disorder, post-traumatic stress disorder, Alzheimer's disease, Parkinson's disease, schizophrenia, frontotemporal dementia, Parkinson's dementia, dementia, Lewy body dementia, multiple system atrophy, or substance abuse.
Study at a glance
| Characteristics | Patent Peer reviewed |
|---|---|
| Interventions | 5-MeO-DMT and MDMA |
| Keywords | Psychedelics Mental health treatment Drug development Neuroscience Therapeutic compounds |
| Citations | 4 |
| Key finding | Prodrugs of DMT, 5-MeO-DMT, and MDMA are described that could potentially treat a range of neurological and psychiatric conditions. |
Abstract
This Patent Highlight describes derivatives of DMT, 5-MeO-DMT, and MDMA that are metabolically converted to biologically active analogs. When these prodrugs are administered to a subject, they potentially could be used therapeutically in conditions associated with neurological diseases. Furthermore, the disclosure provides methods to potentially treat conditions comprising major depressive disorder, post-traumatic stress disorder, Alzheimer's disease, Parkinson's disease, schizophrenia, frontotemporal dementia, Parkinson's dementia, dementia, Lewy body dementia, multiple system atrophy, or substance abuse.